Studies of new therapies should include:
- Assessment of appropriate markers
- The effect of the compound on its target or pathway affected

To assess kidney function:
Use SCr (serum creatinine) level and ideally one other measurement appropriate to the species and preclinical model of the disease

Assess any alterations to systemic events that may initiate and perpetuate injury

Histologic, fluid-phase, tissue-phase biomarkers and pathways should be studied, as appropriate to the disease and the model(s) chosen


Visual Abstract by Denisse Arellano, MD
Twitter @deniise_am